- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06311968
The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor
March 13, 2024 updated by: Jian Chen
Prospective Phase II Clinical Study of R0/R1 Post-operative Proton Radiation Therapy for Thymus Epithelial Malignancies
To observe the efficacy and toxicities of post-operative (R0/R1) proton radiotherapy for locally advanced primary thymus epithelial malignancies.
The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was overall survival and cause-specific survival.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation.
Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation.
Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.
The primary endpoint was progression-free survival and toxicities, and the secondary endpoint was overall survival and cause-specific survival.
Study Type
Interventional
Enrollment (Estimated)
55
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jing Li
- Phone Number: 86-21-38296678
- Email: jing.li@sphic.org.cn
Study Contact Backup
- Name: Kun Liu
- Phone Number: 86-21-38296678
- Email: kun.liu@sphic.org.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 201513
- Recruiting
- Shanghai Proton and Heavy Ion Center
-
Contact:
- Jing Li
- Phone Number: 86-21-38296678
- Email: jing.li@sphic.org.cn
-
Contact:
- Kun Liu
- Phone Number: 86-21-38296678
- Email: kun.liu@sphic.org.cn
-
Principal Investigator:
- Jingfang Mao, PHD
-
Principal Investigator:
- Jian Chen, MD
-
Principal Investigator:
- Kai-liang Wu, PHD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients with stage II-III (Masaoka-Koga) thymus epithelial malignancies without a history of thoracic radiation therapy, who have undergone radical surgery and have a definite pathological diagnosis, and undergone surgery for R0 (no microscopic residual disease) or R1 (microscopic residual disease) resection, and have indication of postoperative radiation therapy.
- Sign informed consent.
- Between the ages of 18 and 70.
- ECOG general status score of 0-2.
- The expected survival is at least 6 months.
- Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x 109/L, platelet count ≥80 x 109/L, hemoglobin ≥9 g/dL 2). Lung function: FEV1>25%, DLCO>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin <1.5 times the upper limit of normal value, and AST, ALT<2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times the upper limit of normal or calculated creatinine clearance ≥50 ml /min, and urinary protein <2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less.
Exclusion Criteria:
- Complicated with other malignant tumors that have not been controlled.
- Have large quantity of pleural or pericardial effusion.
- Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs.
- Chest radiation therapy or radioactive particle implantation history.
- Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area.
- HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis.
- A history of mental illness may hinder the completion of treatment.
- With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy.
- Other circumstances that the physician considers inappropriate to participate in clinical study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study arm
Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation.
Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation.
Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.
|
Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation.
Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation.
Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.
combined platinum based chemotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease progression-free survival rate
Time Frame: From date of radiotherapy started until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.
|
Disease progression-free survival rate was defined from the start of carbon ion radiotherapy till the date of disease progression at any site or death, or the last follow up.
|
From date of radiotherapy started until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.
|
Incidence of Treatment-induced Adverse Events
Time Frame: From date of radiotherapy started, every 3-4 months within the first 2 years, every 6 months between years 3 and 5, and annually thereafter, assessed up to 100 months.
|
Treatment-induced toxicities were scored using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, for events observed after the first dose of irradiation.
Toxicities occurred 90 or more days after the completion of CIRT were defined as late toxicities.
|
From date of radiotherapy started, every 3-4 months within the first 2 years, every 6 months between years 3 and 5, and annually thereafter, assessed up to 100 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival rate
Time Frame: From date of radiotherapy started until the date of death from any cause, assessed up to 100 months.
|
Overall survival rate was defined from the start of carbon ion radiotherapy till the date of death or the last follow-up.
|
From date of radiotherapy started until the date of death from any cause, assessed up to 100 months.
|
Cause-specific survival rate
Time Frame: From date of radiotherapy started until the date of death caused by non-small cell lung cancer treated in this study, assessed up to 100 months.
|
Cause-specific survival rate was defined from the start of carbon ion radiotherapy till the date of death caused by non-small cell lung cancer treated in this study or the last follow-up.
|
From date of radiotherapy started until the date of death caused by non-small cell lung cancer treated in this study, assessed up to 100 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jingfang Mao, PHD, Shanghai Proton and Heavy Ion Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2024
Primary Completion (Estimated)
February 28, 2027
Study Completion (Estimated)
February 28, 2027
Study Registration Dates
First Submitted
March 9, 2024
First Submitted That Met QC Criteria
March 13, 2024
First Posted (Actual)
March 15, 2024
Study Record Updates
Last Update Posted (Actual)
March 15, 2024
Last Update Submitted That Met QC Criteria
March 13, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- SPHIC-TR-THLC2023-07
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Radiation Toxicity
-
University of Milano BicoccaRecruiting
-
Essentia HealthCompleted
-
Centre Francois Baclesse, LuxembourgBIONEXT; NEOLYS DIAGNOSTICS - ALARA GROUPNot yet recruitingCancer | Radiation Toxicity | Radiosensitivity
-
UNC Lineberger Comprehensive Cancer CenterRecruitingToxicity | Radiation ToxicityUnited States
-
Duke UniversityCompletedChemotherapeutic Toxicity | Radiation Therapy ComplicationUnited States
-
Shandong Cancer Hospital and InstituteUnknownAdvanced Cancer | Radiation Toxicity | RadiosensitivityChina
-
NeolysCentre Francois Baclesse; Centre Hospitalier Universitaire de CaenNot yet recruitingPediatric Cancer | Radiation Toxicity | Radiosensitivity
-
Mayo ClinicCompletedQuality of Life | Cancer | Radiation Toxicity | Relaxation During Radiation TherapyUnited States
-
Centre Leon BerardRecruitingRadiation Toxicity | Radiation Dermatitis | Breast AdenocarcinomaFrance
Clinical Trials on Proton radiotherapy
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Massachusetts General HospitalCompleted
-
Proton Collaborative GroupRecruitingBreast Cancer | Breast Neoplasm | Breast Tumor | Cancer of the BreastUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI); Dana-Farber Cancer InstituteActive, not recruitingAstrocytoma | Brain Tumor | Ependymoma | Ganglioglioma | Low Grade GliomaUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
Uppsala UniversityKarolinska University Hospital; Sahlgrenska University Hospital, Sweden; University... and other collaboratorsRecruitingArteriovenous Malformation | Central Nervous System TumourSweden
-
Proton Collaborative GroupActive, not recruitingBreast Cancer | Breast Neoplasm | Breast Tumor | Cancer of the BreastUnited States
-
Washington University School of MedicineRecruitingMetastatic Cancer | Unresectable Solid TumorUnited States
-
Loma Linda UniversityActive, not recruiting
-
University of AarhusCentre Leon Berard; University College London Hospitals; Aarhus University Hospital and other collaboratorsRecruitingEsophageal Cancer | Radiotherapy | Proton Therapy | Side EffectUnited Kingdom, France, Belgium, Denmark, Germany, Italy, Netherlands, Switzerland
-
Umeå UniversityRegion VästerbottenRecruitingAnal Cancer Squamous CellSweden